Preclinical data at the EuroMAbNet Annual Meeting

RNS Number : 3799A
Scancell Holdings Plc
23 September 2022
 

23 September 2022

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell to present preclinical data on proprietary GlyMab ® and AvidiMab ®

  antibody platforms at the EuroMAbNet 12th Annual Meeting

 

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it will present two posters today at the EuroMAbNet 12th Annual Meeting, taking place in Hamburg, Germany, between 22-24 September 2022.

 

The poster entitled "Unlocking the unique potential of AvidiMab®  in fighting cancer" will highlight new data on the Company's AvidiMab ® and GlyMab ® technologies. Scancell has generated certain anti-glycan monoclonal antibodies (GlyMab ® ) that the Company believes have potential as cancer therapies. These GlyMab ® candidates were subsequently avidity-enhanced, leading to heightened anti- tumour activity in vivo, by applying Scancell's AvidiMab®  platform, a proprietary technology for engineering the Fc region of antibodies. The Company compared the interaction of the avidity enhanced CD40-targeted GlyMab® and a non-enhanced antibody with CD40, a tumour necrosis factor receptor (TNFR) superfamily member which plays a critical role in B and T cell immunobiology. The AvidiMab® modified antibody showed superior CD40 binding coinciding with improved B cell expansion compared with the non-enhanced antibody.

 

In the poster entitled "GlyMabs, glycome-targeting monoclonal antibodies for cancer therapy", Scancell outlines the enhanced targeting and binding specifics for candidates created from the GlyMab ® technology. The four humanised monoclonal antibodies (mAbs) targeting glycans on lipids and/or proteins include candidates SC129, SC88, SC134 and SC27. The research shows that the Company's GlyMab® candidates are highly specific for targets found in a broad range of cancers, making them viable candidates for cancer therapeutics.

 

Copies of the poster will be available on Scancell's website following the conference at: https://www.scancell.co.uk/antibody-publications

 

Prof Lindy Durrant, Chief Executive Officer, Scancell , commented: "Our proprietary antibody platforms leverage our skills and knowledge in immunology and we are excited about the future potential they give in creating truly differentiated product candidates for the treatment of certain types of cancer. The preclinical data being presented at EuroMAbNet illustrates the versatility and specificity of our platforms in generating novel antibody drug candidates using our GlyMab ® technology and enhancing their anti-cancer potential with AvidiMab ®. "

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

 

For further information, please contact:




Scancell Holdings plc

+44 (0) 20 3727 1000

Dr John Chiplin, Executive Chairman


Professor Lindy Durrant, CEO




Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Freddy Crossley/Emma Earl (Corporate Finance)


Rupert Dearden (Corporate Broking)




Stifel Nicolaus Europe Limited (Joint Broker)

+44 (0) 20 7710 7600

Nicholas Moore/ Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)


Nick Adams/Nick Harland (Corporate Broking)




FTI Consulting

+44 (0) 20 3727 1000

Simon Conway/Rob Winder/Alex Davis


 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope ® and ImmunoBody ® for vaccines and GlyMab® and AvidiMab ® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope ® and ImmunoBody ® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab ® ).

 

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEWESEEESEDU
UK 100

Latest directors dealings